Key Takeaways
- •Increased muscle growth
- •Increased long bone growth
- •Increased fat metabolism
- •Enhanced wound healing
- •Enhanced slow-wave sleep
CJC-1295: A Synthetic GHRH Analog for Research
CJC-1295 represents one of the earliest synthetic derivatives of growth hormone releasing hormone (GHRH) . Structurally, it comprises the first 29 amino acids of endogenous GHRH combined with a half-life prolonging moiety known as DAC (Drug Affinity Complex) . This peptide was developed to create a more soluble GHRH analog that could be efficiently produced in large quantities while extending the duration of GHRH activity. CJC-1295 functions as a full agonist at the GHRH receptor.
Investigating CJC-1295 and Weight Loss in Research
CJC-1295 acts as a potent stimulator of growth hormone (GH) release from the anterior pituitary gland. Research demonstrates that by mimicking the actions of endogenous GHRH, CJC-1295 can elevate GH levels in murine models by 2- to 10-fold. Owing to its prolonged half-life, the effects of CJC-1295 can persist for up to six days following administration [1].
By increasing circulating GH concentrations, CJC-1295 has been associated with:
- Increased muscle growth
- Increased long bone growth
- Increased fat metabolism
- Enhanced wound healing
- Enhanced slow-wave sleep
- Enhanced cognition
Studies indicate that CJC-1295 facilitates both muscle accretion and fat oxidation. In research involving mice with an ablated GHRH gene, while GHRH injections failed to normalize growth and restore body composition, CJC-1295 succeeded in doing so. Notably, CJC-1295 achieved these effects at half the dose required for GHRH in the same trials. Mice treated with CJC-1295 exhibited normal body weight, whereas controls became obese [2].
It is important to note that the relationship between GH levels and obesity is complex. However, activities that naturally elevate GH—such as resistance exercise, intermittent fasting, reduced sugar intake, and proper nutrient consumption (particularly essential amino acids)—have been linked to weight loss. This suggests that weight loss may not be directly caused by diet or exercise alone, but rather that these behaviors stimulate GH release, which in turn drives changes in body composition. Animal studies support this concept, showing reduced obesity and increased muscle mass when GH release is enhanced.
CJC-1295 and Basal Metabolic Rate
Lean body mass, particularly muscle tissue, plays a critical role in caloric expenditure. The greater an individual's muscle mass, the higher their baseline metabolic rate. By increasing lean body mass in animal models, CJC-1295 exerts a substantial influence on the number of calories that can be consumed before they are stored as fat. Consequently, research suggests that CJC-1295 not only enhances fat oxidation but also elevates the threshold for fat deposition, making it more difficult for the body to store fat and easier to mobilize existing fat stores.
Additional Research Findings on CJC-1295
Growth hormone influences more than just body composition. Studies indicate that elevated GH levels can improve sleep quality, enhance cognitive function, and accelerate wound healing—particularly in skin and tendon tissues. Compounds that augment GH release, such as CJC-1295, have been shown in animal studies to benefit cardiovascular health, mitigate dementia-related processes, accelerate tendon repair, and improve both the onset and duration of slow-wave sleep. Increased slow-wave sleep is linked to muscle recovery and improved memory consolidation. Thus, by enhancing sleep quality, CJC-1295 may further support muscle building and weight loss. Additionally, CJC-1295 has been associated with improvements in fertility in certain experimental contexts [3].
Numerous GH secretagogues are currently under investigation, each with distinct additional effects. A distinguishing feature of CJC-1295 is its ability to preserve normal GH release patterns. In animal studies, although CJC-1295 increased the total amount of GH secreted from the anterior pituitary, it maintained the pulsatile nature of GH release [4]. This characteristic is thought to potentially reduce side effects—such as excessive long bone growth—that are observed with some other GH secretagogues.
CJC-1295 vs. CJC-1295 DAC: Clarifying Terminology
Considerable confusion exists regarding the precise identity of CJC-1295. Some sources describe it as simply the first 29 amino acids of GHRH, while others insist it includes the DAC moiety. The original developer of DAC, ConjuChem Biotechnologies, referred to the DAC-containing molecule as CJC-1295. Therefore, in its original form, CJC-1295 denotes the first 29 amino acids of GHRH with DAC attached. To avoid ambiguity, it has become standard practice to refer to the DAC-containing variant as CJC-1295-DAC. When DAC is absent, the peptide should be correctly termed Modified GRF (1-29) or CJC-1295-no DAC.
DAC is a specialized peptide construct appended to the terminal end of the first 29 amino acids of GHRH (GRF) to enhance stability in circulation. Under normal conditions, GRF persists in the bloodstream for only minutes before being degraded. With the addition of DAC, the half-life of GRF extends from minutes to nearly twenty-four hours—significantly longer than the natural GH spikes observed in the body.
Summary of CJC-1295 Research for Weight Loss
As a GH secretion enhancer, CJC-1295 has been shown in research to increase muscle building, improve sleep quality, and promote fat oxidation. Its unique chemical structure confers a long half-life and potent effects while potentially minimizing adverse effects. Animal studies indicate that CJC-1295 is at least as effective as natural GHRH, when administered at appropriate doses, in normalizing GH secretion. Ongoing research is exploring the combination of CJC-1295 with another class of GH secretagogues—growth hormone secretagogue receptor (GHSR) agonists, such as ipamorelin. These peptides stimulate GH release through a distinct mechanism. Preliminary animal studies suggest that co-administration of CJC-1295 with GHSR agonists results in enhanced GH release compared to either peptide class alone.
References
[1] S. L. Teichman, A. Neale, B. Lawrence, C. Gagnon, J.-P. Castaigne, and L. A. Frohman, “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults,” J. Clin. Endocrinol. Metab., vol. 91, no. 3, pp. 799–805, Mar. 2006, doi: 10.1210/jc.2005-1536.
[2] M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006, doi: 10.1152/ajpendo.00201.2006.
[3] V. A, C. G, B. A, G. G, A. Pg, and G. Ar, “Clinical use of growth hormone-releasing factor for induction of superovulation.,” Hum. Reprod. Oxf. Engl., vol. 6, no. 9, Oct. 1991, doi: 10.1093/oxfordjournals.humrep.a137517.
[4] M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, Dec. 2006, doi: 10.1210/jc.2006-1702.
Reviewed by the Volta Peptides Research Team